News Briefing channel feed

Pri­or­i­ty re­view for Gami­da's cell ther­a­py; PhI­II shut­tered at Akari; Im­mutep drops da­ta on LAG3 study

3 years ago

Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

3 years ago

FDA ac­cepts Lex­i­con's heart fail­ure re­sub­mis­sion; Bris­tol My­ers buys out mava­camten roy­al­ties

3 years ago

Galectin gets $60M cred­it line from bil­lion­aire chair; In­flam­ma­to­ry dis­ease biotech reach­es SPAC deal

3 years ago

No­var­tis gener­ics arm files for MS biosim­i­lar, chal­leng­ing Bio­gen; Pluris­tem short­ens name

3 years ago

Ver­tex wins 'break­through' nod for non-opi­oid pain drug; Af­ter US with­draw­al, EMA re­stricts Clo­vis' Rubra­ca

3 years ago

F-star lines up Take­da pact weeks af­ter M&A ex­it; En route to Eu­rope de­ci­sion, Gen­Sight touts 5-year da­ta

3 years ago

Apel­lis nabs pri­or­i­ty re­view for ge­o­graph­ic at­ro­phy pitch; Bris­tol My­ers ex­tends of­fer time­line on Turn­ing Point buy­out

3 years ago

An old epilep­sy med gets oral liq­uid for­mu­la­tion nod; PMV pairs up AS­CO stand­out with Keytru­da

3 years ago

Vir CSO de­part­ing next month to be Al­tos CMO; Bob Dug­gan’s Sum­mit Ther­a­peu­tics and the FDA try to make head­way

3 years ago

Mubadala Cap­i­tal-backed on­col­o­gy biotech adds more cash to Se­ries A; Opti­nose shares pooled da­ta on nasal spray

3 years ago

Con­nect shrinks time­line for atopic der­mati­tis da­ta; Bi­cy­cle's wheels keep turn­ing with Genen­tech

3 years ago

Trio of biotechs raise funds to make en­zymes and de­vel­op drugs for IBS and oth­er au­toim­mune dis­eases

3 years ago

Astel­las finds an­oth­er col­lab­o­ra­tor in small UK start­up; Two Japan­ese biotechs align on gene ther­a­pies

3 years ago

9 Me­ters Bio­phar­ma and Cara Ther­a­peu­tics tout mid-stage da­ta for gas­troin­testi­nal, pru­ri­tus stud­ies

3 years ago

Gray­bug seeks al­ter­na­tive op­tions for eye drugs; RA-backed epilep­sy out­fit se­cures $40M Se­ries C

3 years ago

Mi­to­chon­dria biotech re­ceives Morn­ing­side buy­out of­fer af­ter PhII fail; On­col­o­gy mi­cro­cap with­draws IPO plans

3 years ago

Ever­est Med­i­cines reach­es its first peak in Chi­na with Trodelvy nod; Cy­cle­ri­on touts da­ta in small study

3 years ago

Im­mat­ics and Ed­i­tas part­ner on gene edit­ing and T cells; Eye­n­ovia founder to step down from CEO po­si­tion

3 years ago

EU re­port­ed­ly eye­ing vac­cines deal for mon­key­pox out­break; Nas­daq tells Mereo to get stock price up or face delist­ing

3 years ago

Biotech SPAC takes IPO goal down a notch; Africa’s top health agency warns against mon­key­pox vac­cine hoard­ing

3 years ago

Chica­go-area biotech sends 2nd drug to In­di­a's reg­u­la­tors; Pen­ny stock play­er spins out PhI­II can­cer can­di­date in­to new com­pa­ny

3 years ago

FDA ac­cepts pri­or­i­ty re­view of CSL-uniQure he­mo­phil­ia B gene ther­a­py; Fo­s­un Phar­ma nets an­oth­er deal

3 years ago

A cell ther­a­py biotech finds a de­liv­ery part­ner; FDA re­moves clin­i­cal hold on Ocu­gen's Covid can­di­date

3 years ago
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times